Skip to main content

Advertisement

Table 4 Multivariate analysis of 30-day all-cause mortality due to neutropenic pneumonia

From: Treatment of community-onset pneumonia in neutropenic cancer patients: β-lactam monotherapy versus combination antibiotic regimens

Variables Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Lung cancer 3.55 (1.13–11.15) 0.030 1.60 (0.30–8.63) 0.586
Palliative setting 4.83 (1.09–21.43) 0.038 58.61 (0.26–13,356.90) 0.142
Duration of neutropenia 1.08 (1.03–1.15) 0.003 1.27 (1.05–1.53) 0.013
CRP 1.04 (1.00–1.08) 0.035 1.06 (1.00–1.11) 0.021
MASCC risk index 0.80 (0.68–0.95) 0.010 0.80 (0.65–0.99) 0.042
Combination therapy 0.27 (0.09–0.85) 0.025 0.85 (0.20–3.67) 0.827
Types of β-lactams
 Cefepime 0.28 (0.10–0.81) 0.019 0.64 (0.17–2.46) 0.518
 Ceftazidime 2.05 (0.58–7.25) 0.268   
 Piperacillin-tazobactam 1.42 (0.40–5.02) 0.589   
 Carbapenem 5.95 (1.89–18.70) 0.002 0.28 (0.01–50.00) 0.631
  1. Abbreviations: CI confidence interval, CRP C-reactive protein, HR hazard ratio, MASCC Multinational Association for Supportive Care in Cancer